A Phase II clinical trial evaluating Dovitinib in advanced squamous non-small cell lung cancer (NSCLC) patients with FGFR1 amplification did not observe a clear correlation between FGFR1 amplification levels and partial response (PR) rates. The gene discussed is FGFR1; the disease is non-small cell squamous lung carcinoma.